Hyposmia
20
3
5
11
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
15%
3 trials in Phase 3/4
27%
3 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (20)
Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial
Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults
Study of CYR-064 Versus Placebo in Patients.
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Study of Olfactory Disorders in Patients With Cardiac Amyloidosis
Treatment of Postviral Olfactory Dysfunction
Topical Versus Injection PRP for Olfactory Dysfunction
Treatment of Olfactory Dysfunction Using Vagus Nerve Stimulation
Mechanical and Sensorial Training in the Olfactive Rehabilitation of Patients With Total Laryngectomy
Olfactory Training on Smell Dysfunction Patients in HK
Olfactory Training in COVID-19 Associated Loss of Smell
Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19
The Vietnamese Smell Identification Test in the Diagnosis of Parkinson's Disease
Smell in Covid-19 and Efficacy of Nasal Theophylline
Olfactory Disfunction and Co-ultraPEALut
Intranasal Insulin for COVID-19-related Smell Loss
Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell
The Clinical Applicability of the 'TIB' Olfactory Test Device